Lv4
530 积分 2024-05-01 加入
Discovery andCharacterization of RP04340 : A Highly Potent and OrallyActive Pan-KRAS PROTAC Degrader
22天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
1个月前
已完结
Tirzepatide vs. Semaglutide for Obesity Treatment
1个月前
已完结
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors
1个月前
已完结
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
1个月前
已完结
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
2个月前
已完结
Battle of GLP-1 delivery technologies
2个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
2个月前
已完结
皖公网安备34019202002308
